Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 190.00
Bid: 185.00
Ask: 195.00
Change: 0.00 (0.00%)
Spread: 10.00 (5.405%)
Open: 190.00
High: 190.00
Low: 190.00
Prev. Close: 190.00
SNX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

23 Apr 2020 07:00

RNS Number : 5549K
Synectics PLC
23 April 2020
 

 

 

 

 

23 April 2020

 

 

Synectics plc

("Synectics", the "Company" or the "Group")

 

Business Update

Synectics plc (AIM: SNX), a leader in the design, integration and support of advanced security and surveillance systems, provides the following update ahead of its Annual General Meeting ("AGM") to be held later this morning.

Further to the Company's announcement of 23 March 2020, the Board continues to closely monitor the effect of the Coronavirus (COVID-19) pandemic on Synectics' customers, business and employees. Management is making necessary decisions daily to meet the evolving situation and is closely following all national government regulations and guidance wherever the Company operates.

The Company has a solid cash position and measures in place to ensure that it remains financially sound during this period of uncertainty and beyond. The Group's available consolidated net cash balance was £3.3 million as of 20 April 2020, with confirmed facilities of £5.0 million in place if required.

The Board has taken mitigating actions to preserve the Group's cash and protect the business, including:

· Reducing temporarily salaries and fees for the Board and senior management team across the Group;

· Utilising the UK Government's Job Retention Scheme in order to protect jobs, with 30% of the Company's UK workforce having been furloughed in two tranches during April;

· Applying for support, as appropriate, from government schemes in the US, Germany and Singapore designed to protect jobs; and

· Suspending all discretionary spending, recruitment and capital expenditure in addition to withdrawing the resolution to recommend payment of the final dividend at the AGM.

Business Operations

All the Company's business units are currently operating, but at significantly reduced levels of activity in every sector and geography. Reasonable levels of design and planning work are continuing for projects now expected to proceed later in the year than originally anticipated.

We continue to provide essential service and support to our customers on-site where required and have increased our remote support capabilities. The Company's business is to provide security and safety systems; employees and customers are well aware of the role they play in protecting communities around the world and we are making every effort to ensure that customers can continue to rely on us at this difficult time.

Planned investment in software development continues, with only limited impact as a result of COVID-19.

People

With most staff working from home and others furloughed, we have instigated a specific programme to keep colleagues connected to the business and each other. The Group is making extensive use of video conferencing and other communication tools to facilitate continued effective teamwork and to minimise any potential sense of isolation.

Outlook

Synectics' priorities continue to be:

· to protect the health and well-being of its employees and customers;

· to provide ongoing support to its customers, especially where we are providing essential security and safety; and

· to manage the business for the long term by prudent actions to preserve cash and maintain capability.

As announced on 23 March 2020, and given the continued uncertainty in global markets, financial guidance on the Company's expected trading performance for the financial year ending 30 November 2020 has been and remains suspended.

Regular updates are provided on the Company's website and further announcements will be made as appropriate.

David Coghlan, Chairman of Synectics, commented:

 "Synectics is a global business with a solid balance sheet, and we have taken immediate measures to contain costs and protect our financial position.

"The Company fills a number of important roles in the wider security and surveillance industry. The Board is determined that Synectics will maintain its skills, resources and product development momentum and, by doing so, be well-placed for new opportunities that will undoubtedly emerge as we reach the other side of the current hiatus."

For further information, please contact:

Synectics plc

Tel: +44 (0) 114 280 2828

Paul Webb, Chief Executive

David Coghlan, Chairman

 

email: info@synecticsplc.com

www.synecticsplc.com

 

 

Shore Capital

Tel: +44 (0) 20 7408 4050

Tom Griffiths / Henry Willcocks

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDEASLAADPEEFA
Date   Source Headline
4th Feb 20097:00 amRNSInterim Results
16th Jan 200912:06 pmRNSNotification of Results
3rd Sep 20087:00 amRNSPreliminary Results
6th Feb 20087:01 amRNSInterim Results
16th Jan 20087:00 amRNSNotification of Results
6th Dec 20071:09 pmRNSCanc of AIM trading facility
6th Dec 20079:56 amRNSOffer Update
30th Nov 20077:01 amRNSOffer Update
29th Nov 20077:01 amRNSOffer Update
26th Nov 200712:34 pmRNSResult of EGM
23rd Nov 20079:57 amRNSRule 8.1- Synexus
19th Nov 20079:40 amRNSRule 8.1- Synexus
16th Nov 200710:00 amRNSRule 8.1- Synexus
15th Nov 20073:00 pmBUSRule 8.3 - Synexus Clinincal Research Plc
15th Nov 200712:07 pmBUSRule 8.3 - Synexus Clinical Research Plc
15th Nov 20079:16 amRNSRule 8.1- Synexus
14th Nov 20073:21 pmBUSRule 8.3 - Synexus Clinical Research Plc
13th Nov 20073:16 pmBUSRule 8.3 - Synexus Clinical Research Plc
7th Nov 20074:38 pmRNSOffer Document Posted
7th Nov 20077:02 amRNSOffer for Synexus
6th Nov 20079:10 amRNSRule 8.3- Synexus
22nd Oct 200710:46 amRNSHolding(s) in Company
19th Oct 20076:21 pmRNSResponse to price movement
28th Sep 20077:02 amRNSPre Close Statement
5th Sep 20078:33 amRNSBoard Change
5th Sep 20077:01 amRNSPreliminary Results
22nd Aug 20073:17 pmRNSHolding(s) in Company
22nd Aug 200711:19 amRNSAIM RULE 26
15th Jun 20071:26 pmRNSGrant of Options
13th Jun 20077:01 amRNSPreliminary Results
24th May 20074:24 pmRNSNotice of Results
8th Mar 20077:00 amRNSHolding(s) in Company
20th Feb 200712:33 pmRNSGrant of Options
7th Feb 20077:02 amRNSNorth American Contract Wins
7th Feb 20077:02 amRNSInterim Results
6th Feb 200710:14 amRNSDirector/PDMR Shareholding
5th Feb 20077:00 amRNSDirectorate Change
29th Jan 20072:58 pmRNSNotice of Results
26th Jan 20077:01 amRNSTrading Update
28th Dec 20064:36 pmRNSGrant of Options
22nd Dec 20069:37 amRNSTotal Voting Rights & Capital
5th Dec 20067:01 amRNSInterim Results
29th Nov 20063:25 pmRNSDirector/PDMR Shareholding
24th Nov 200611:53 amRNSNotice of Results
24th Oct 20067:01 amRNSAcquisition
4th Oct 20067:00 amRNSTrading Statement
18th Sep 20069:11 amRNSDirectorate Change
13th Jul 20067:01 amRNSIssue of Equity
20th Jun 200610:39 amRNSGrant of Options
14th Jun 20065:06 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.